TrialIO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Trial details
- Registry ID
- NCT05077709
- Phase
- Phase 2
IOBTQ
IO Biotech
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCNCT05077709 | IO Biotech | Phase 2 | Completed | 2025-11-30Actual |
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)NCT05155254 | IO Biotech | Phase 3 | Active not recruiting | 2025-05-30Actual |
| Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsNCT05280314 | IO Biotech | Phase 2 | Recruiting | 2025-04-30Estimated |
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Trial details
- Registry ID
- NCT05155254
- Phase
- Phase 3
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Trial details
- Registry ID
- NCT05280314
- Phase
- Phase 2
Latest recorded trial changes
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
NCT05077709 · IO Biotech
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: ORR or PFS
+ After
Measure: ORR
Primary completion date changed
− Before
4 Jan 2024
+ After
30 Nov 2025
Recruitment status changed
− Before
Active not recruiting
+ After
Completed